Federal Register of Legislation - Australian Government

Primary content

PB 25 of 2021 Determinations/Health as made
This instrument amends the National Health (Continued Dispensing – Emergency Measures) Determination 2020 to make changes to the pharmaceutical benefits eligible to be provided as a Continued Dispensing supply to reflect amendments to the National Health (Listing of Pharmaceutical Benefits) Instrument 2012 (PB 71 of 2012).
Administered by: Health
Registered 31 Mar 2021
Table of contents.

Commonwealth Coat of Arms of Australia

 

PB 25 of 2021

 

National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 3)

I, THEA CONNOLLY, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, and delegate of the Minister for Health and Aged Care, make the following determination.

Dated                   31 March 2021

 

 

 

 

           

THEA CONNOLLY                       

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

 

 

 

 

 

 

                                           


 

 

Contents

1...... Name

2...... Commencement............................................................................................................................... 1

3...... Authority......................................................................................................................................... 1

4 ..... Schedule.......................................................................................................................................... 1

Schedule 1—Amendments                                                                                                                          2

National Health (Continued Dispensing - Emergency Measures) Determination 2020         2

 

 

 


1  Name

(1) This instrument is the National Health (Continued Dispensing – Emergency Measures) Amendment Determination 2021 (No. 3).

(2) This instrument may also be cited as PB 25 of 2021.

2  Commencement

(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 April 2021.

 

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

             (2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

                   This instrument is made under subsection 89A(3) of the National Health Act 1953.

4  Schedules

                   Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.


Schedule 1Amendments

National Health (Continued Dispensing – Emergency Measures) Determination 2020

[1]        Schedule 1, entry for Apomorphine

insert as first entry:

 

Injection containing apomorphine hydrochloride hemihydrate 20 mg in 2 mL

Injection

 

Injection containing apomorphine hydrochloride hemihydrate 50 mg in 5 mL

Injection

[2]        Schedule 1, after entry for Apomorphine in the form Solution for subcutaneous injection containing apomorphine hydrochloride               30 mg in 3 mL pre-filled pen

insert:

 

Solution for subcutaneous infusion containing apomorphine hydrochloride hemihydrate 50 mg in 10 mL pre-filled syringe

Injection

[3]        Schedule 1, entry for Cefuroxime

omit:

 

Powder for oral suspension 125 mg (as axetil) per 5 mL, 70 mL

Oral

[4]        Schedule 1, after entry for Framycetin

insert:

Fulvestrant

Injection 250 mg in 5 mL pre-filled syringe

Injection

[5]        Schedule 1, after entry for Indacaterol with glycopyrronium

insert:

Indacaterol with glycopyrronium and mometasone

Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 136 micrograms (for use in Breezhaler)

Inhalation by mouth

Indacaterol with glycopyrronium and mometasone

Capsule containing powder for oral inhalation indacaterol 114 micrograms (as maleate) with glycopyrronium 46 micrograms (as bromide) and mometasone furoate 68 micrograms (for use in Breezhaler)

Inhalation by mouth

[6]        Schedule 1, omit entry for Nadroparin

[7]        Schedule 1, entry for Paracetamol

omit:

 

Suppositories 500 mg, 24

Rectal

[8]        Schedule 1, after entry for Rizatriptan in the form Wafer 10 mg (as benzoate)

insert:

Romosozumab

Injection 105 mg in 1.17 mL single use pre-filled syringe

Injection

[9]        Schedule 1, after entry for Sertraline in the form Tablet 50 mg (as hydrochloride)

insert:

 

Tablet 50 mg (as hydrochloride) (USP)

Oral

[10]      Schedule 1, after entry for Sertraline in the form Tablet 100 mg (as hydrochloride)

insert:

 

Tablet 100 mg (as hydrochloride) (USP)

Oral